|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | SJWD14080700000148显示文摘 | Emilio Bajetta Laura Catena Nicola Fazio Sara Pusceddu Pamela Biondani Giusi Blanco Sergio Ricci Michele Aieta Francesca Pucci Monica Valente Nadia Bianco Chiara Maria Mauri Francesca Spada | 2014 | Cancer2014，，16： | 1 |
| 2 | Occurrence and patterns of nutritional traits and polycyclic aromatic hydrocarbons(PAHs)in sea cucumber(Holothuria poli)tissues:benefits and risk for human health显示文摘Objectives:The paper evaluates the benefit and risk for human health associated with consumption of sea cucumber Holothuria poli(H.polil from Italian coasts(Central Mediterranean Sea).Materials and Methods:Body wall(BW),internal tunic(ITu),muscle bands(MBs),alimentary canal(AC),gonad(Gd),and respiratory tree(RT)of H.polii were analyzed for proximate composition.Moreover,amino acids(AAs),fatty acids(FAs)and polycyclic aromatic hydrocar bons(PAHs)were determined with high-performance liquid chromatography coupled with ultraviolet-visible spectroscopy(UPLC UV/Vis),gas chromatography-flame ionization detector(GC-FID)and gas chromatography mass spectrometry(GC-MS),respectively.Results:Differences in the contents of total amino acids(TAAs)occurred based on tissue and sex,with AC and MB of female and Gd of male showing higher contents(range 47.8-60.2 g/kg we weight(ww)).Glycine and glutamic acid were the most abundant.Polyunsaturated fatty acid(PUFA)was the major class of FAs and arachidonic acid and eicosapentenoic acid(EPA)were the predominant PUFA.n-3 PUFA showed higher content in Gd,AC,and RT,indicating higher quality.A favorable n-3/n-6 in the range of 1.04-1.67 was observed.PAHs showed values ranging from 23 to 207μg/kg ww with the highest levels in Gd and AC tissues and the lower in BW.Benzo[alpyrene,the most toxic compound,was detected in all tissues,of both sexes,at levels of 1.5-18μg/kg ww.Conclusion:All tissues of H.poli,although with differences among them,are valuable food and can contribute for a healthy diet.Excess cancer risk(CR)values for Gd and AC tissues were above the considerable CR threshold of one in 10000 established by the United States Environmental Protection Agency(USEPA)for high ingestion rate of this seafood. | Francesca Biandolino Isabella Parlapiano Lucia Spada Antonella Di Leo Maria Calo Giovanni Fanelli Ermelinda Prato Santina Giandomenico | 2022 | Food Quality and Safety2022，6，2： | 0 |
| 3 | Looking for the right TNM staging system for pancreatic neuroendocrine tumors显示文摘Pancreatic neuroendocrine tumors(panNETs)represent a rare subgroup of neuroendocrine neoplasms(NENs)which showed an impressive increase of incidence over the last decade(1).As over the same period particularly low stage and low grade NETs had the highest increase it is plausible that small(e.g., | Nicola Fazio Francesca Spada Emilio Bertani | 2021 | Hepatobiliary Surgery and Nutrition2021，10，3： | 0 |
| 4 | Review of recent advances in medical treatment for neuroendocrine neoplasms:somatostatin analogs and chemotherapy显示文摘Neuroendocrine neoplasms(NENs)are a heterogeneous group of rare tumours often producing high levels of hormones and causing symptoms.There are a number of different types of NENs.They usually arise as advanced and low/intermediate grade only in a minority of cases,as high grade.Treatment depends on which type and may include surgery,interventional radiology,and systemic treatment,including chemotherapy,somatostatin analogs,interferonα2b,peptide receptor radionuclide therapy,and only for pancreatic neuroendocrine tumors,molecular targeted agents,including everolimus and sunitinib.The aim of the article is to review the medical approaches with somatostatin analogs and chemotherapy.The treatment of NENs is mainly based on their biological characteristics of aggressiveness and functional features,such as symptoms and endocrine markers. | Francesca Spada Monica Valente | 2016 | Journal of Cancer Metastasis and Treatment2016，2，1： | 0 |
| 5 | Advanced small-bowel well-differentiated neuroendocrine tumours:An international survey of practice on 3rd-line treatment显示文摘BACKGROUND Somatostatin analogues are an established first-line therapy for well differentiated small bowel neuroendocrine tumours(Wd-SBNETs),while and peptide receptor radionuclide therapy(PRRT)is frequently used as a second-line therapy.Adequate treatment selection of third-line treatment remains challenging due to the limited prospective data currently available on the best therapeutic sequence.AIM To understand current practice and rationale for decision-making by physicians in the 3rd-line setting by building an online survey.METHODS Weighted average(WA)of likelihood of usage between responders(1 very unlikely;4 very likely)was used to reflect the relevance of factors explored.RESULTS Replies from representatives of 28 centers were received(5/8/2020-21/9/2020);medical oncologist(53.6%),gastroenterologist(17.9%);United Kingdom(21.4%),Spain(17.9%),Italy(14.3%).Majority from European Neuroendocrine Tumor Society(ENETS)Centres of Excellence(57.1%),who followed ENETS guidelines(82.1%).Generally speaking,3rd-line treatment for Wd-SBNETs was:everolimus(EVE)(66.7%),PRRT(18.5%),liver embolization(LE)(7.4%)and interferon-alpha(IFN)(3.7%);chemotherapy(0%);decision was based on clinical trial data(59.3%),or personal experience(22.2%).EVE was most likely used if Ki-67<10%(WA 3.27/4)or age<70 years(WA 3.23/4),in the 3rd-line setting(WA 3.23/4);regardless of presence/absence of carcinoid syndrome(CS),rate of progression or extent of disease.Chemotherapy was mainly utilised only if rapid progression(within 6 mo)(WA 3.35/4),Ki-6710%-20%(WA 2.77/4),negative somatostatin receptor imaging(WA 2.65/4)or high tumour burden(WA 2.77/4);temozolomide or streptozocin was used with capecitabine or 5-fluorouracil(5-FU)(57.7%),FOLFOX(5-FU combined with oxaliplatin)(23.1%).LE was selected if presence of CS(WA 3.24/4)or Ki-67<10%(WA 2.8/4),after progression to other treatments(WA 2.8/4).IFN was rarely used(WA 1.3/4).CONCLUSION Everolimus was the most frequently used therapeutic option in the third-line setting.The most important factors for decision-making included Ki-67,rate of progression,functionality and tumour burden;since this decision is based on multiple factors,it highlights the need for a multidisciplinary assessment. | Angela Lamarca Mauro Cives Louis de Mestier Joakim Crona Francesca Spada KjellÖberg Marianne Pavel Teresa Alonso-Gordoa | 2021 | World Journal of Gastroenterology2021，27，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员